BMCC-2022-V04

Recombinant Lipoprotein Technology in Cancer Immunotherapy

BMCC

Recombinant Lipoprotein Technology in Cancer Immunotherapy

未定中標題
BMCC Targeted indication

HPV-associated cancer

BMCC Status

Preclinical study

BMCC Key features
  • High safety profile
  • Highly immunogenic protein
  • The platform technology could be applied to different vaccine products.
BMCC Market

The fusion protein made using this technology can be alone as a vaccine candidate or mixed with a carrier, such as an adjuvant, in vaccines or as a medicament for immune modulation.

In vaccination, subunit vaccines are likely the new generation vaccines because of their safety and efficiency. This technology has been applied in meningococcal group B subunit vaccine (MGBvac), dengue subunit vaccine, and HPV-based immunotherapeutic vaccines.

We expect this technology to be used in the development of new and better vaccines, especially for the unmet medical need disease areas.

MODE OF ACTION

 Recombinant lipoprotein can trigger both innate and adaptive immunity

EXPERIMENTAL RESULTS

in vitro efficacy

Induction of dendritic cells activation through TLR2

in vivo efficacy

Inhibition of large tumor growth

Safety pharmacology and general toxicology

Non-toxiin SinglDose Acute Toxicity Testing (At doses up to 10 times of the effective dose in animal).

INTELLECTUAL PROPERTY

Granted patents:
US patents: US7,833,776; US8,426,163; US8771990
Taiwan patent: TW I354023; TW I376385

SELECTED PUBLICATIONS

1. Chang et al. OncoImmunology. 5: e1095433, 2016
2. Shen et al. Expert Rev Vaccines 2015, 14(3):383-94
3. Chang et al. Mol. Cancer. 2014, 13:60
4. Huang et al. PLoS ONE 7: e40970. 2012
5. Leng et al. Mol. Immunol. 47: 2015-2021 (2010)
6. Chen et al. Vaccine 27:1400-9 (2009)

BUSINESS OPPORTUNITY

License out and/or Collaboration and Sponsored Research

CONTACT

service@biip-dcc.org

*欲下載完整檔案請 登入/ 會員註冊